Page last updated: 2024-12-05

propylparaben

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propylparaben, also known as propyl p-hydroxybenzoate, is a synthetic organic compound classified as a paraben. Parabens are widely used as preservatives in cosmetics, pharmaceuticals, and food products due to their antimicrobial properties. Propylparaben is particularly effective against bacteria and fungi, contributing to the extended shelf life of these products. It is synthesized by reacting p-hydroxybenzoic acid with propyl alcohol. While generally considered safe for topical use, concerns have emerged regarding potential endocrine disruption and allergic reactions. Research studies are ongoing to assess the long-term effects of propylparaben exposure, especially in relation to hormone regulation and potential health risks. The increasing awareness of these potential concerns has led to growing consumer demand for paraben-free products. This demand has prompted further research into alternative preservatives to ensure the safety and efficacy of cosmetic, pharmaceutical, and food products.'

Parabens: Methyl, propyl, butyl, and ethyl esters of p-hydroxybenzoic acid. They have been approved by the FDA as antimicrobial agents for foods and pharmaceuticals. (From Hawley's Condensed Chemical Dictionary, 11th ed, p872) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7175
CHEMBL ID194014
CHEBI ID32063
SCHEMBL ID977
MeSH IDM0048132

Synonyms (185)

Synonym
BIDD:ER0229
MLS002152934 ,
smr000112070
STL294815
propyl chemosept
propyl parasept
n-propyl p-hydroxybenzoate
chemacide pk
nipazol
solbrol p
p-hydroxypropyl benzoate
p-hydroxybenzoic propyl ester
nsc-8511
aseptoform p
bonomold op
p-hydroxybenzoic acid, propyl ester
propyl butex
chemocide pk
propylparasept
propagin
4-hydroxybenzoic acid, propyl ester
propyl paraben
tegosept p
propyl p-hydroxybenzoate
wln: qr dvo3
94-13-3
protaben p
nipasol p
paseptol
nipagin p
nsc8511
preserval p
betacide p
propyl chemsept
propyl aseptoform
propylparaben ,
propyl 4-hydroxybenzoate
pulvis conservans
nipasol m
nipasol
benzoic acid, 4-hydroxy-, propyl ester
nsc-23515
nsc23515
85403-59-4
n-propylparaben
peph
bayer d 206
betacine p
n-propyl-p-hydroxybenzoate
propyl-4-hydroxybenzoate
NCGC00090965-01
NCGC00090965-02
propylparaben [usan]
4-hydroxybenzoic acid propyl ester
p-hydroxybenzoic acid propyl ester
hsdb 203
fema number 2951
pulvis conservans (van)
ai3-01341
fema no. 2951
propylester kyseliny p-hydroxybenzoove [czech]
nsc 23515
benzoic acid, p-hydroxy-, propyl ester
epa pesticide chemical code 061203
brn 1103245
einecs 202-307-7
propyl parahydroxybenzoate
caswell no. 714
p-oxybenzoesaurepropylester [german]
inchi=1/c10h12o3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11h,2,7h2,1h
propyl 4-hydroxybenzoate, bioxtra
propylparaben (nf)
D01422
propyl parahydroxybenzoate (tn)
propyl parahydroxybenzoate (jp17)
4-hydroxybenzoic acid propylester
NCGC00090965-03
n-propyl 4-hydroxybenzoate
propyl-paraben
propyl 4-hydroxybenzoate, >=99%
MLS002222346
chebi:32063 ,
e216
propylparaben e216
CHEMBL194014
propyl para-hydroxybenzoate
propylis hydroxybenzoas
paratexin p
paraben p
H0219
A844839
propyl 4-oxidanylbenzoate
NCGC00090965-04
NCGC00090965-06
NCGC00090965-05
parabens
tox21_400012
cas-94-13-3
dtxsid4022527 ,
dtxcid602527
P1955
tox21_111048
HMS2268K21
AKOS008948099
propylparaben [usan:nf]
4-10-00-00374 (beilstein handbook reference)
p-oxybenzoesaurepropylester
unii-z8ix2sc1oh
propylester kyseliny p-hydroxybenzoove
z8ix2sc1oh ,
ec 202-307-7
FT-0618698
n-propyl paraben
p-oxybenzoesaeurepropylester
S5405
BBL023754
propylparaben [fcc]
propylparaben [mi]
propyl parahydroxybenzoate [ep monograph]
methyl parahydroxybenzoate impurity c [ep impurity]
propyl parahydroxybenzoate [jan]
propyl paraben [vandf]
propylparaben [who-dd]
propylparaben [ii]
propyl parahydroxybenzoate [ep impurity]
propylis hydroxybenzoas [who-ip latin]
propylparaben [hsdb]
propyl p-hydroxybenzoate [fhfi]
propyl hydroxybenzoate [who-ip]
propyl (4-hydroxybenzoate)
propylparaben [inci]
propylparaben [usp-rs]
propylparaben [vandf]
propyl hydroxybenzoate [mart.]
propyl hydroxybenzoate
MLS006011654
36M ,
SCHEMBL977
Q-201635
AC-34533
n-propyl-p-hydroxy-benzoate
lexgard p
component of heb-cort mc (salt/mix)
p-hydroxybenzoic acid n-propyl ester
chemoside pk
4-hydroxybenzoic acid, n-propyl ester
1219802-67-1
bdbm70190
cid_7175
mfcd00002354
propylparaben, certified reference material, tracecert(r)
propyl 4-hydroxybenzoate, saj first grade, >=98.0%
propylparaben, united states pharmacopeia (usp) reference standard
propyl 4-hydroxybenzoate, tested according to ph.eur.
propyl parahydroxybenzoate, european pharmacopoeia (ep) reference standard
propyl 4-hydroxybenzoate, vetec(tm) reagent grade, 98%
propylparaben, pharmaceutical secondary standard; certified reference material
propyl 4-hydroxybenzoate, p.a., 99.0-100.5%
4-hydroxybenzoic acid-propyl ester
propylparaben, usan
DS-3427
Q511627
DB14177
propyl-4-hydroxybenzoate,(s)
4-hydroxybenzoic acid-propyl ester 1000 microg/ml in acetonitrile
propyl parahydroxybenzoate 1.0 mg/ml in methanol
propyl parahydroxybenzoate 0.01 mg/ml in methanol
propyl parahydroxybenzoate;propyl 4-hydroxybenzoate
HY-N2026
CS-0018518
CCG-266432
NCGC00090965-07
4-hydroxybenzoic acid-propyl ester d7 (propyl d7)
propyl 4-?hydroxybenzoate
(propyl paraben)
n-propyl 4-hydroxybenzoate--d4
EN300-7419478
propyl parahydroxybenzoate (ep monograph)
propyl parahydroxybenzoate (ep impurity)
propyl p-oxybenzoate
usepa/opp pesticide code: 061203
propylparaben (usp-rs)
propylparaben (ii)
propyl hydroxybenzoate (mart.)
methyl parahydroxybenzoate impurity c (ep impurity)

Research Excerpts

Overview

Propylparaben (PPB) is an antimicrobial preservative widely used in food, cosmetics, and pharmaceutics. It poses a potential threat to aquatic ecosystems.

ExcerptReferenceRelevance
"Propylparaben (PrP) is a widely used preservative that is constantly detected in aquatic environments and poses a potential threat to aquatic ecosystems. "( Endocrine Disruption of Propylparaben in the Male Mosquitofish (
Huang, L; Li, Y; Liang, Y; Ma, Y; Song, X; Wang, H; Yang, T; Zeng, H, 2023
)
2.66
"Propylparaben (PPB) is an antimicrobial preservative widely used in food, cosmetics, and pharmaceutics. "( Propylparaben reduces the excitability of hippocampal neurons by blocking sodium channels.
Galván, EJ; Lara-Valderrábano, L; Rocha, L, 2016
)
3.32

Toxicity

ExcerptReferenceRelevance
"5 mg/ml or higher, adverse effects were not completely reversible."( Adverse effects of lidocaine and methylparaben on tracheal ciliary activity.
Dreisin, RB; LaForce, FM; Manawadu, BR; Mostow, SR, 1979
)
0.26
" In the comparative toxic effects based on cell viability, ATP level, and rhodamine 123 retention, butyl- and isobutyl-parabens were more toxic than propyl- and isopropyl-parabens, and ethyl- and methyl-parabens and p-hydroxybenzoic acid were less toxic than propyl-paraben."( Mechanism of p-hydroxybenzoate ester-induced mitochondrial dysfunction and cytotoxicity in isolated rat hepatocytes.
Moldéus, P; Nakagawa, Y, 1998
)
0.3
"The relationship between mitochondrial membrane permeability transition (MPT) and the toxic effects of the alkyl esters of p-hydroxybenzoic acid (parabens) has been studied in mitochondria and hepatocytes isolated from rat liver."( Role of mitochondrial membrane permeability transition in p-hydroxybenzoate ester-induced cytotoxicity in rat hepatocytes.
Moore, G; Nakagawa, Y, 1999
)
0.3
" Some animal studies have reported adverse reproductive effects of parabens."( Safety assessment of esters of p-hydroxybenzoic acid (parabens).
Burdock, GA; Carabin, IG; Soni, MG, 2005
)
0.33
" Acute toxicity studies in animals indicate that parabens are not significantly toxic by various routes of administration."( Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
, 2008
)
0.57
" Other compounds do not stay long in the body, but still cause toxic effects during the time they are present."( Toxic effects of the easily avoidable phthalates and parabens.
Crinnion, WJ, 2010
)
0.36
" Diluted Free N Clear was not mutagenic in a bacterial reverse mutation assay that tested concentrations extending into the toxic range, and did not increase the frequency of micronucleated polychromatic erythrocytes in bone marrow cells of male or female Sprague-Dawley rats when tested at the maximum permissible dose volume of 20 mL/kg bw."( Safety studies conducted on a sanitizing agent containing benzalkonium chloride.
Burdock, GA; Dolan, LC; Wheeler, JA, 2013
)
0.39
"The need for developing efficient and safe alternatives to parabens has been growing in the cosmetic and pharmaceutical industries."( β-Alkylated oligomaltosides as new alternative preservatives: antimicrobial activity, cytotoxicity and preliminary investigation of their mechanism of action.
Djedaïni-Pilard, F; Helle, F; Marçon, F; Moreau, V; Mullié, C; Thiebault, N, 2013
)
0.39
" The dose of 1000 mg/kg/day was the no-observed adverse effect level, corresponding to a maximum plasma concentration of 12,030 ng/ml and exposure to 47 760 ng · h/ml (AUC0-8 h) at the end of the treatment."( Oral propylparaben administration to juvenile male Wistar rats did not induce toxicity in reproductive organs.
Gazin, V; Marguerite, F; Marsden, E, 2013
)
0.9
" extract ameliorates the toxic effects of BPA and is proved to have antioxidant potential and antitoxic effect."( Influence of Genista tinctoria L. or methylparaben on subchronic toxicity of bisphenol A in rats.
Bolfa, P; Cătoi, C; Crişan, G; Kiss, B; Loghin, F; Păltinean, R; Pop, A; Popa, DS; Vlase, L, 2014
)
0.4
" Therefore, the application of AOPs to remove MPB should be carefully performed for safe water treatment."( Computational consideration on advanced oxidation degradation of phenolic preservative, methylparaben, in water: mechanisms, kinetics, and toxicity assessments.
An, T; Fang, H; Gao, Y; Ji, Y; Li, G, 2014
)
0.4
" In assessing the aquatic toxicity of parabens and their degradation products using the model calculations, the products of the (•)OH-addition route were found to be more toxic to green algae than original parabens."( Theoretical investigation on the kinetics and mechanisms of hydroxyl radical-induced transformation of parabens and its consequences for toxicity: Influence of alkyl-chain length.
An, T; Gao, Y; Ji, Y; Li, G, 2016
)
0.43
" Fenton process was applied to reduce the organic charge and toxic properties of the model effluents."( Application of Fenton oxidation to reduce the toxicity of mixed parabens.
Corceiro, V; Costa, R; Gmurek, M; Ledakowicz, S; Martins, RC; Quinta-Ferreira, ME; Quinta-Ferreira, RM; Rossi, AF, 2016
)
0.43
" Exposure to methylparaben (MP) has been associated with adverse health outcomes, therefore, an alternative compound, 1,2-hexanediol (1,2-H), has been applied for cosmetics."( Phototoxicity and chronic toxicity of methyl paraben and 1,2-hexanediol in Daphnia magna.
Ji, K; Kho, Y; Lee, J; Lee, K; Park, N, 2017
)
0.46
"Butylparaben sodium (BP), sodium diacetate (SDA) and potassium sorbate (PS) are safe and internationally recognized preservatives."( Comparative toxic effects of butylparaben sodium, sodium diacetate and potassium sorbate to Dunaliella tertiolecta and HL7702 cells.
Chen, HH; Jiang, JG; Shang, Y; Xu, XL, 2017
)
0.46
" We conducted a comprehensive study to determine whether propylparaben (PP) administration to juvenile rats is associated with adverse effects on reproductive development and function."( Safety assessment of propylparaben in juvenile rats.
Brodie, T; Graziano, M; McNerney, ME; Pouliot, L; Sivaraman, L; Wang, B, 2018
)
1.05
" However, butyl paraben and derivatives, such as isobutyl parabens, are classified as allergens and have been shown to induce toxic effects."( Assessment of hepatotoxicity and dermal toxicity of butyl paraben and methyl paraben using HepG2 and HDFn in vitro models.
Glassey, J; Kizhedath, A; Wilkinson, S, 2019
)
0.51
" Nevertheless, many of these chemical additives pose toxic effects to the human body, exhibiting health risks from a mild hypersensitivity to life-threatening anaphylaxis or lethal intoxication."( An insight into toxicity and human-health-related adverse consequences of cosmeceuticals - A review.
Bilal, M; Iqbal, HMN, 2019
)
0.51
"Methylparaben (MeP) is one of the most used preservatives in the industry; however, the toxic effects on aquatic ecosystems are still poorly understood."( Toxicity of methylparaben to green microalgae species and derivation of a predicted no effect concentration (PNEC) in freshwater ecosystems.
Guimarães, PS; Martins, CMG; Martins, SE; Puerta, YT, 2020
)
0.56
" In order to investigate the mechanisms of toxic action and the efflux pumps involved in their detoxication, we used a strategy with batteries of Schizosaccharomyces pombe yeast strains, either defective in cell signalling, in detoxification pumps, or in cell surveillance mechanisms."( Investigation of mechanisms of toxicity and exclusion by transporters of the preservatives triclosan and propylparaben using batteries of Schizosaccharomyces pombe strains.
Álvarez-Herrera, C; Maisanaba, S; Repetto, G, 2020
)
0.77
" Because the use of cosmetics shows an increasing trend and some adverse health outcomes of parabens present in these products have been reported, the present review focused on the safety of dermal application of these compounds."( Review of the safety of application of cosmetic products containing parabens.
Brzóska, MM; Galicka, A; Matwiejczuk, N, 2020
)
0.56
"Recently, we discovered that the cosmetic preservatives, benzalkonium chloride and formaldehyde, are especially toxic to human meibomian gland epithelial cells (HMGECs)."( Toxicity of the cosmetic preservatives parabens, phenoxyethanol and chlorphenesin on human meibomian gland epithelial cells.
Kam, WR; Li, Y; Liu, Y; Sullivan, DA; Wang, J, 2020
)
0.56
" Its widespread use resulted in the contamination of aquatic environment and raised concerns about the potential adverse effects on human health, especially in the developing organisms."( Embryotoxicity of methylparaben to zebrafish (Danio rerio) early-life stages.
Amorena, M; Angelozzi, G; Bozzelli, M; Conte, A; Merola, C; Perugini, M, 2020
)
0.56
" Here, we seek to provide a balanced perspective on the most significant purported adverse health effects, and thereby allay the many misconceptions regarding the safety of parabens."( A perspective on the safety of parabens as preservatives in wound care products.
Brackman, G; Torfs, E, 2021
)
0.62
" In this study, the persistence of three widely used parabens; methyl-, propyl-, and butyl paraben in soil and their toxic effects on the soil invertebrate, Eisenia fetida was investigated."( Persistence of the parabens in soil and their potential toxicity to earthworms.
Aitken, RJ; Arachchige Chamila Samarasinghe, SV; Krishnan, K; Megharaj, M; Naidu, R, 2021
)
0.62
" We conclude that inadequate evidence has been provided for the safe use of PP in food, cosmetics, and consumer products."( Assessing the Public Health Implications of the Food Preservative Propylparaben: Has This Chemical Been Safely Used for Decades.
Bugos, J; Vandenberg, LN, 2021
)
0.86
" These chemicals have been considered safe for many years."( Thirteen-week subcutaneous repeated dose toxicity study of butylparaben and its toxicokinetics in rats.
Bae, JS; Choi, YK; Kim, KB; Lee, BM; Lee, JD; Shin, CY; Shin, HC; Song, SW, 2021
)
0.62
" This study demonstrates the adverse effects of PP on ovarian estradiol secretion and ovulation, further evaluates the safety of PP as a preservative, and provides guidance for the use of PCPs and cosmetics by women of childbearing age."( Propylparaben concentrations in the urine of women and adverse effects on ovarian function in mice in vivo and ovarian cells in vitro.
Chu, W; Du, Y; Geng, X; Jiao, L; Li, H; Li, S; Wang, D; Zhai, J, 2021
)
2.06
" They have received attention recently due to findings that demonstrate estrogenic impacts and other adverse effects of parabens."( Identifying potential paraben transformation products and evaluating changes in toxicity as a result of transformation.
Cobb, GP; Penrose, MT, 2022
)
0.72
" Therefore, this study provides new insights into the toxic effects and potential mechanism of benzylparaben in fish, especially from the aspect of lipid metabolism."( Toxic effects of waterborne benzylparaben on the growth, antioxidant capacity and lipid metabolism of Nile tilapia (Oreochromis niloticus).
Han, F; Jia, Y; Li, E; Lin, H; Xia, C; Zhang, J; Zhao, Q, 2022
)
0.72
"Some pharmaceutical excipients may cause adverse reactions, excipient-related interactions and/or contraindications."( Pharmaceutical excipients with potential to cause adverse effects in paediatric nasal medicines.
Canji-Panic, JM; Komazec, ZS; Lalic-Popovic, MN; Stjepanovic, AN; Tesic, TZ; Todorovic, NB, 2022
)
0.72
"As emerging organic pollutants, parabens are of global concern because of their ubiquitous presence and adverse effects."( Disparate toxicity mechanisms of parabens with different alkyl chain length in freshwater biofilms: Ecological hazards associated with antibiotic resistome.
Chen, J; Hu, B; Liu, S; Shan, X; Wang, C; Wang, P; Wang, X, 2023
)
0.91
"The widespread occurrence of methylparaben (MPB) has aroused great concern due to its weak estrogenic endocrine-disrupting property and potential toxic effects."( Methylparaben toxicity and its removal by microalgae Chlorella vulgaris and Phaeodactylum tricornutum.
Chang, X; Chen, L; Ding, J; He, Y; Lv, M; Ren, S; Song, L, 2023
)
0.91
" Higher long-chained parabens were more toxic than short-chained parabens, as determined by the M-POD values of 154."( Transcriptome analysis reveals differences in developmental neurotoxicity mechanism of methyl-, ethyl-, and propyl- parabens in zebrafish embryos.
Kim, KT; Ra, JS; Rhyu, DY; Tran, CM, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" This method was used to determine the pharmacokinetic parameters of melphalan following high-dose (140 mg/m2) intravenous administration in patients with advanced malignancies undergoing peripheral blood hematopoietic progenitor-cell transplantation."( High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies.
Astre, C; Bressolle, F; Grosse, PY; Joulia, JM; Martel, P; Pinguet, F, 1996
)
0.29
" The utility of Lipo-MD for determination of lipophilic substances to perform pharmacokinetic study was suggested."( Lipo-microdialysis: a new microdialysis method for studying the pharmacokinetics of lipophilic substances.
Kawasaki, H; Kurosaki, Y; Nakamura, S; Shiojiri, Y, 1998
)
0.3
" Plasma Cmax and AUC values after oral or subcutaneous doses were 4- to 10-fold higher relative to respective values after dermal administration."( Systemic exposure to parabens: pharmacokinetics, tissue distribution, excretion balance and plasma metabolites of [14C]-methyl-, propyl- and butylparaben in rats after oral, topical or subcutaneous administration.
Ameller, T; Aubert, N; Legrand, JJ, 2012
)
0.38
" The present LC-MS/MS method was successfully applied to pharmacokinetic studies of taxifolin after intravenous administration of taxifolin, oral administration of its physical mixture and nanodispersion."( UHPLC-MS/MS Determination, Pharmacokinetic, and Bioavailability Study of Taxifolin in Rat Plasma after Oral Administration of its Nanodispersion.
Gao, MJ; Kuang, HX; Lv, JN; Meng, YH; Mi, YY; Wang, ZB; Yang, BY; Yang, CJ, 2016
)
0.43
" Although pharmacokinetic studies on parabens have been conducted in animals, limited information exists on their pharmacokinetic profiles in humans."( Pharmacokinetic profile of propyl paraben in humans after oral administration.
Choi, JW; Kim, S; Lee, J; Lee, S; Shin, C; Shin, MY, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"Fifteen extraction sockets packed with a new drug combination which includes a local anaesthetic (cincain chloride), a local antiseptic (tri-iodomethane) and two drugs with a potent antifibrinolytic activity (tranexamic acid and propyl-hydroxy-benzoic acid) in an absorbable gelatin sponge (Gelfoam) as a vehicle, were histologically assessed with special reference to the parameters related to wound healing."( The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report.
Syrjänen, KJ; Syrjänen, SM, 1981
)
0.26
"This study evaluated supercritical fluid extraction (SFE) combined with liquid chromatography-mass spectrometry (LC-MS) to determine trace preservatives and antioxidants including methylparaben (MP), ethylparaben (EP), propylparaben (PP), butylparaben (BP), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), alpha-tocopherol (alpha-t) and alpha-tocopherol acetate (alpha-ta) in cosmetic products."( Simultaneous analysis of antioxidants and preservatives in cosmetics by supercritical fluid extraction combined with liquid chromatography-mass spectrometry.
Lee, MR; Li, ZG; Lin, CY; Tsai, TF, 2006
)
0.52
" Our results point to a low risk of increased genotoxic effects of AgNP when used in combination with aluminium salts, butylparaben or di-n-butylphthalate in consumer products."( Genotoxic effects in transformed and non-transformed human breast cell lines after exposure to silver nanoparticles in combination with aluminium chloride, butylparaben or di-n-butylphthalate.
Cieślak, M; Domeradzka-Gajda, K; Grobelny, J; Kozajda, A; Puchowicz, D; Ranoszek-Soliwoda, K; Roszak, J; Smok-Pieniążek, A; Spryszyńska, S; Stępnik, M; Tomaszewska, E, 2017
)
0.46
" The PI particles were prepared by pneumatic spray combined with the immersion-precipitation phase transformation method."( Porous polyimide particle-coated adsorptive microextraction bar combined with thermal desorption-gas chromatography for rapid determination of parabens in condiments.
Li, Y; Wu, D; Yan, X; Zhan, Y; Zhong, D, 2019
)
0.51
"This study was undertaken to assess cytotoxic effects of selected aluminium compounds, parabens and phthalates in combination with silver nanoparticles (AgNP, 15 and 45 nm by STEM, Ag15 and Ag45, respectively) on cell lines of the human breast epithelium, normal (MCF-10A) and transformed (MDA-MB-231 and MCF-7)."( Cytotoxic effects in transformed and non-transformed human breast cell lines after exposure to silver nanoparticles in combination with selected aluminium compounds, parabens or phthalates.
Celichowski, G; Cieślak, M; Domeradzka-Gajda, K; Grobelny, J; Kowalczyk, K; Puchowicz, D; Ranoszek-Soliwoda, K; Roszak, J; Smok-Pieniążek, A; Spryszyńska, S; Stępnik, M; Świercz, R; Tomaszewska, E, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"In order to improve the bioavailability of insulin after rectal application to rabbits, the influence of surface-active amino acid-fatty acid condensate on absorption and, the effects of a protease inhibitor (aprotinine), of a disinfectant (methyl-hydroxybenzoate) and of chemotherapeutics (chloramphenicol, ambazone and metronidazole) were investigated."( The protection of insulin against proteolytic processes after rectal application to normoglycemic rabbits.
Hacker, E; Kossowicz, J; Milde, K, 1991
)
0.28
"Both the partitioning parameters to the oral mucosa and the absorption rate constants to the blood circulation correlated to the lipophilicities of the compounds in all mucosa."( Perfusion cells for studying regional variation in oral-mucosal permeability in humans. I: Kinetic aspects in oral-mucosal absorption of alkylparabens.
Kimura, T; Kurosaki, Y; Yano, K, 1997
)
0.3
" The absorption rate constant, the partition to oral mucosa and the residence time in oral mucosa increased with lipophilicity of the compound."( Perfusion cells for studying regional variation in oral-mucosal permeability in humans. I: Kinetic aspects in oral-mucosal absorption of alkylparabens.
Kimura, T; Kurosaki, Y; Yano, K, 1997
)
0.3
"Effects of bioavailability on degradation of 14C-p-hydroxybenzoate were examined using sterile soil inoculated with Arthrobacter sp."( Effects of moisture and sorption on bioavailability of p-hydroxybenzoic acid to Arthrobacter sp. in soil.
Ballance, AR; Ellsworth, TR; Johnson, TA; Sims, GK, 1999
)
0.3
" Poor ocular bioavailability of drugs (< 1%) from conventional eye drops is due mainly to the precorneal loss factors that include rapid tear turnover, nonproductive absorption, transient residence time in the cul-de-sac, and the relative impermeability of the drugs to corneal epithelial membrane."( Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system.
Gupta, H; Jain, S; Mathur, R; Mishra, AK; Mishra, P; Velpandian, T, 2007
)
0.34
" More DEP than DBP was absorbed, presumably because of a faster absorption rate for DEP."( Urinary excretion of phthalates and paraben after repeated whole-body topical application in humans.
Andersson, AM; Frederiksen, H; Janjua, NR; Skakkebaek, NE; Wulf, HC, 2008
)
0.35
"The rate of absorption at 15 min was calculated to be 13."( Relationship between lipophilicity and absorption from the liver surface of paraben derivatives and antipyrine in rats.
Fumoto, S; Kobayashi, M; Miyamoto, H; Nakamura, J; Nishida, K; Sasaki, H; Yoshikawa, N, 2011
)
0.37
"The rate of absorption of a drug from the liver surface could be estimated from physicochemical properties such as lipophilicity and molecular weight."( Relationship between lipophilicity and absorption from the liver surface of paraben derivatives and antipyrine in rats.
Fumoto, S; Kobayashi, M; Miyamoto, H; Nakamura, J; Nishida, K; Sasaki, H; Yoshikawa, N, 2011
)
0.37
" Overall, parabens were well absorbed after oral and subcutaneous, and partially absorbed after dermal administration."( Systemic exposure to parabens: pharmacokinetics, tissue distribution, excretion balance and plasma metabolites of [14C]-methyl-, propyl- and butylparaben in rats after oral, topical or subcutaneous administration.
Ameller, T; Aubert, N; Legrand, JJ, 2012
)
0.38
" This paper focused on dermal absorption rate and effectiveness of first-pass biotransformation of methylparaben (MP) under in-use conditions of skincare products."( Dermal absorption and hydrolysis of methylparaben in different vehicles through intact and damaged skin: using a pig-ear model in vitro.
Hojerová, J; Klimová, Z; Lucová, M; Pažoureková, S, 2013
)
0.39
" Isolation and identification of these metabolites may be used as references for in vivo bioavailability experiments and for investigating their bioactivity in in vitro experiments."( Development and Validation of an in vitro Experimental GastroIntestinal Dialysis Model with Colon Phase to Study the Availability and Colonic Metabolisation of Polyphenolic Compounds.
Bosscher, D; Breynaert, A; Claeys, M; Cos, P; Hermans, N; Kahnt, A; Pieters, L, 2015
)
0.42
"Anthocyanins are being increasingly investigated for their neuroprotective and antineuroinflammatory effects; however, the overall bioavailability of many anthocyanins is relatively low."( Comparison of the Neuroprotective and Anti-Inflammatory Effects of the Anthocyanin Metabolites, Protocatechuic Acid and 4-Hydroxybenzoic Acid.
Arora, Y; Brenner, MC; Byars, C; Linseman, DA; Punessen, N; Snodgrass, M; Winter, AN, 2017
)
0.46
" Strategies that may enhance substrate bioavailability such as surfactant production and chemotactic responses toward aromatic compounds were confirmed."( New Findings on Aromatic Compounds' Degradation and Their Metabolic Pathways, the Biosurfactant Production and Motility of the Halophilic Bacterium Halomonas sp. KHS3.
Corti Monzón, G; Herrera Seitz, MK; Murialdo, SE; Nisenbaum, M, 2018
)
0.48
"9 fold in terms of bioavailability as compared to the pure drug."( Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug.
Fatima, Z; Kaur, CD; Nashik, SS; Rizvi, DA; Srivastava, D; Tulsankar, SL, 2019
)
0.51
"The prepared cocrystal was found to be relatively more soluble than the pure drug and also showed an enhanced oral bioavailability as compared to the pure drug."( Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug.
Fatima, Z; Kaur, CD; Nashik, SS; Rizvi, DA; Srivastava, D; Tulsankar, SL, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"An understanding of the bioavailability of topically applied cosmetics ingredients is key to predicting their local skin and systemic toxicity and making a safety assessment."( Comparison of the metabolism of 10 cosmetics-relevant chemicals in EpiSkin™ S9 subcellular fractions and in vitro human skin explants.
Arbey, E; Cubberley, R; Duplan, H; Eilstein, J; Ellison, C; Fabre, A; Géniès, C; Grégoire, S; Hewitt, NJ; Jacques-Jamin, C; Klaric, M; Lange, D; Rothe, H; Schepky, A, 2020
)
0.56
" The main reasons for variability seem to be limited water solubility of parabens, determining their bioavailability at the cellular level, and absence of metabolic activation in the Comet Assay."( Comparison of methods used for evaluation of mutagenicity/genotoxicity of model chemicals - parabens.
Chrz, J; Dvořáková, M; Hošíková, B; Jírová, G; Kejlová, K; Kolářová, H; Malina, L; Mannerström, M; Očadlíková, D; Svobodová, L; Vlková, A, 2020
)
0.56
" We searched PubMed databases for animal studies and clinical trials evaluating chemicals recognized as thyroid disruptors -perchlorate, phthalates, bisphenol A-, as well as chemicals with potential thyroid disruption activity -parabens, pesticides and persistent organic pollutants, on thyroid hormones (THs) levels and their bioavailability during pregnancy, and the outcome in newborns, infants and children."( Neurodevelopmental impact of the offspring by thyroid hormone system-disrupting environmental chemicals during pregnancy.
Cisternas, P; Inestrosa, NC; Salazar, P; Villaseca, P, 2021
)
0.62

Dosage Studied

A new HPLC-RP method has been developed and validated for the simultaneous determination of benzocaine, two preservatives (propylparaben (nipasol) and benzyl alcohol) and degradation products.

ExcerptRelevanceReference
" The excretion rate of BHQ glucuronide for 24h after dosing with BHT-acid was about 9-fold higher than that after dosing with BHT."( Further metabolism of 3,5-di-tert-butyl-4-hydroxybenzoic acid, a major metabolite of butylated hydroxytoluene, in rats.
Mizutani, T; Tajima, K; Takemura, M; Yamamoto, K, 1991
)
0.28
" The dose-response curves show the typical sigmoidal pattern."( Ciliotoxicity of methyl- and propyl-p-hydroxybenzoates: a dose-response and surface-response study.
Jian, L; Li Wan Po, A, 1993
)
0.29
"Significant impairment of BCG viability, dependent on dosage and time of co-incubation, was noted with all lubricants analyzed."( The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
Böhle, A; Braasch, H; Jocham, D; Rüsch-Gerdes, S; Ulmer, AJ, 1996
)
0.29
" The recovery of haloperidol in synthetic mixtures with parabens and pharmaceutical dosage forms is also reported."( Zero-crossing derivative spectrophotometry for the determination of haloperidol in presence of parabens.
Bouzouita, K; Kallel, M; Ouanês, S; Safta, F; Trabelsi, H, 1998
)
0.3
"A capillary electrophoresis method was developed to separate and quantitate ephedrine (ED), theophylline (TP) and phenobarbital (PB) in a tablet dosage form."( Determination of ephedrine, theophylline and phenobarbital in a tablet dosage form by capillary electrophoresis.
Haque, A; Stewart, JT; Xu, X, 1999
)
0.3
" The method is simple and accurate and therefore suitable for the simultaneous determination of these compounds in dosage form."( High-performance liquid chromatographic method for the assay of dexamethasone and xylometazoline in nasal drops containing methyl p-hydroxybenzoate.
Agbaba, D; Boberic-Borojevic, D; Eric, S; Milojevic, Z; Ristic, P; Solujic, M, 2002
)
0.31
" Maternal food consumption was significantly decreased in the highest dose group over the dosing period (GD 6-20)."( Developmental toxicity evaluation of butylparaben in Sprague-Dawley rats.
Daston, GP, 2004
)
0.32
" At a specific pH condition, the applied alum dosage would efficiently decrease the turbidity to 2 NTU follows the order: humic>tannic>p-hydroxybenzoic acid."( Effects of polyelectrolytes on reduction of model compounds via coagulation.
Chang, EE; Chao, SH; Chiang, PC; Hsing, HJ; Tang, WY, 2005
)
0.33
"A new HPLC-RP method has been developed and validated for the simultaneous determination of benzocaine, two preservatives (propylparaben (nipasol) and benzyl alcohol) and degradation products of benzocaine in a semisolid pharmaceutical dosage form (benzocaine gel)."( A new validated method for the simultaneous determination of benzocaine, propylparaben and benzyl alcohol in a bioadhesive gel by HPLC.
García-Montoya, E; Miñarro, M; Orriols, A; Pérez-Lozano, P; Suñé-Negre, JM; Ticó, JR, 2005
)
0.77
" The proposed method can be utilized for the routine analysis of the four analytes in pharmaceutical dosage form."( Stability indicating reversed-phase liquid chromatographic determination of metronidazole benzoate and diloxanide furoate as bulk drug and in suspension dosage form.
Mishal, A; Sober, D, 2005
)
0.33
"A stability indicating high performance liquid chromatography procedure has been developed for the simultaneous determination of guaifenesin (GUA), methyl p-hydroxybenzoate (MHB) and propyl p-hydroxybenzoate (PHB) in a commercial cough syrup dosage form."( Simultaneous, stability indicating, HPLC-DAD determination of guaifenesin and methyl and propyl-parabens in cough syrup.
Allegrone, G; Del Grosso, E; Grosa, G; Russo, R, 2006
)
0.33
" Thus, the formulation approach offers the possibility of formulating and controlling the in vitro release of water-insoluble drugs from solid oral dosage forms."( Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system.
Booth, S; Clarke, A; Newton, M; Serratoni, M, 2007
)
0.34
"Two HPLC-UV methods are described for the separate determination of artemether (AM) and the combined preservatives, methylparaben and propylparaben in a pharmaceutical dosage form."( Assay of artemether, methylparaben and propylparaben in a formulated paediatric antimalarial dry suspension.
Atemnkeng, MA; Marchand, E; Plaizier-Vercammen, J, 2007
)
0.81
" The proposed method is rapid and sensitive and, therefore, suitable for the routine control of these ingredients in multicomponent dosage forms."( Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.
El-Dawy, MA; Elbarbry, FA; Mabrouk, MM,
)
0.13
"Most medicines are available only as solid, adult-strength dosage forms from which oral extemporaneous liquids are often prepared for children."( Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
Ghulam, A; Keen, K; Long, PF; Tuleu, C; Wong, IC, 2007
)
0.34
" Moreover, these monographs should take into account testing that simulates multiple dosing from a single storage container during the intended in-use shelf life of multidose extemporaneous preparations."( Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
Ghulam, A; Keen, K; Long, PF; Tuleu, C; Wong, IC, 2007
)
0.34
"A methodology following International Cooperation on Harmonization for Veterinary Products (VICH) guidelines for the stability evaluation of colistin sulfate in a nonaqueous suspension pharmaceutical dosage form for veterinary use (via their drinking water) is described."( Application of a validated method in the stability study of colistin sulfate and methylparaben in a veterinary suspension formulation by high-performance liquid chromatography with a diode array detector.
García-Montoya, E; Miñarro, M; Orriols, A; Pérez-Lozano, P; Suñé-Negre, JM; Ticó, JR,
)
0.13
" In the equal effect dosage joint treatment of PP and BP, uterus proliferation effects were observed at the doses of 1 and 1/2 LOEL, but the effect was not observed at the doses of 1/4 LOEL."( [Enhancement of di-n-butyl phthalate on the estrogenic activities of esters of p-hydroxybenzoic acid].
Chang, B; Ge, J; Liang, Y, 2007
)
0.34
" Pregnant Wistar rats were dosed from gestational day (GD) 7 to GD 21, followed by examination of the dams, and the fetuses."( Do parabens have the ability to interfere with steroidogenesis?
Axelstad, M; Boberg, J; Frederiksen, H; Hansen, PR; Hass, U; Nellemann, C; Taxvig, C; Vinggaard, AM, 2008
)
0.35
" The data show response and distribution of ethyl paraben and butyl paraben in maternal rat plasma, pools of amniotic fluids, placenta, whole-body fetuses, and in fetal liver after dosing of dams with 100, 200, and 400 mg/kg body weight (bw)/day from gestational day 7 to 21."( Higher levels of ethyl paraben and butyl paraben in rat amniotic fluid than in maternal plasma after subcutaneous administration.
Frederiksen, H; Hass, U; Nellemann, C; Taxvig, C; Vinggaard, AM, 2008
)
0.35
"A simple and precise stability-indicating liquid chromatography method is developed and validated for the quantitative simultaneous estimation of irbesartan (IRB) and hydrochlorothiazide (HCTZ) in combined pharmaceutical dosage form."( Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations.
Patil, KR; Rane, VP; Sangshetti, JN; Shinde, DB; Yeole, RD, 2010
)
0.36
" Plasma PP concentrations were quantifiable up 8h after dosing with a mean T max value of 15 min."( Oral propylparaben administration to juvenile male Wistar rats did not induce toxicity in reproductive organs.
Gazin, V; Marguerite, F; Marsden, E, 2013
)
0.9
" The increase in Ru/CeO2 dosage led to a progressive enhancement in the oxidation rate of BP by permanganate at neutral pH."( Ruthenium nanoparticles supported on CeO2 for catalytic permanganate oxidation of butylparaben.
Bao, H; Guan, X; Huang, Y; Qiao, J; Sun, B; Wang, H; Zhang, J; Zhou, G, 2013
)
0.39
" We observed a monotonic dose-response relationship between the total number of products used and urinary paraben and phthalate metabolite concentrations."( Personal care product use and urinary phthalate metabolite and paraben concentrations during pregnancy among women from a fertility clinic.
Braun, JM; Calafat, AM; Hauser, R; Just, AC; Smith, KW; Williams, PL,
)
0.13
"Modern solid multiparticulate drug forms (minitablets, pellets, granules) can provide the possibility of precise dosing or modified drug release or taste masking for medicines used in children."( Application properties of oral gels as media for administration of minitablets and pellets to paediatric patients.
Kluk, A; Sznitowska, M, 2014
)
0.4
" In 19-month-old male offspring, epididymal sperm counts were lower than controls, and in ventral prostate an overrepresentation of findings related to hyperplasia was observed in exposed groups compared with controls, particularly in the group dosed with anti-androgens."( Late-life effects on rat reproductive system after developmental exposure to mixtures of endocrine disrupters.
Axelstad, M; Boberg, J; Christiansen, S; Hass, U; Isling, LK; Jacobsen, PR; Kortenkamp, A; Mandrup, KR; Taxvig, C; Vinggaard, AM, 2014
)
0.4
"87%) in the dosing range of concentrations."( Simultaneous determination of some phthalate metabolites, parabens and benzophenone-3 in urine by ultra high pressure liquid chromatography tandem mass spectrometry.
Charlier, C; Dewalque, L; Dubois, N; Pirard, C, 2014
)
0.4
" Overall, the model provided very good agreement with published time-course data in blood and urine from controlled dosing studies in rat and human, and demonstrates the potential value of quantitative IVIVE in expanding the use of human biomonitoring data in safety assessment."( A case study on quantitative in vitro to in vivo extrapolation for environmental esters: Methyl-, propyl- and butylparaben.
Campbell, JL; Clewell, HJ; Yoon, M, 2015
)
0.42
" The obtained new knowledge can be helpful for the development of novel coating materials (based on QPM-MAS blends) for controlled-release dosage forms."( Quaternary polymethacrylate-magnesium aluminum silicate films: Water uptake kinetics and film permeability.
Pongjanyakul, T; Rongthong, T; Siepmann, F; Siepmann, J; Sungthongjeen, S, 2015
)
0.42
" So there are strict rules on the dosage of sodium methylparaben in every country."( [Determination of the Sodium Methylparaben Content Based on Spectrum Fluorescence Spectral Technology and GA-BP Neural Network].
Chen, DY; Hou, PG; Wang, ST; Wang, XL; Wang, ZF; Wei, M, 2015
)
0.42
" In this study, we investigated metabolism and urinary excretion of methyl paraben (MeP), iso-butyl paraben (iso-BuP) and n-butyl paraben (n-BuP) after oral dosage of deuterium-labeled analogs (10 mg)."( Metabolism and elimination of methyl, iso- and n-butyl paraben in human urine after single oral dosage.
Angerer, J; Brüning, T; Dierkes, G; Koch, HM; Moos, RK, 2016
)
0.43
" The commercially available tablets of 5 and 10mg do not provide the necessary flexibility in dosing needed for treating children."( Design and stability study of an oral solution of amlodipine besylate for pediatric patients.
Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016
)
0.43
" Microbiological quality was studied in an 18-week in-use test based on a two-times daily dosing schedule."( Design and stability study of an oral solution of amlodipine besylate for pediatric patients.
Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016
)
0.43
" This liquid formulation is preferred over manipulated commercial dosage forms or non-standardized extemporaneously compounded formulations."( Design and stability study of an oral solution of amlodipine besylate for pediatric patients.
Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2016
)
0.43
" In the case of liquid dosage forms, besides the active substance in large amounts there are usually also inactive ingredients such as methyl- and propylparaben."( A Novel Two-Step Liquid-Liquid Extraction Procedure Combined with Stationary Phase Immobilized Human Serum Albumin for the Chiral Separation of Cetirizine Enantiomers along with M and P Parabens.
Bączek, T; Chmielewska, A; Konieczna, L, 2016
)
0.63
"A novel and simple ultra-performance LC method was developed for the estimation of nadifloxacin (NAD), terbinafine hydrochloride (TBH), mometasone furoate (MMF), methyl paraben (MP), and propyl paraben (PP) in a topical pharmaceutical dosage formulation."( Stability-Indicating UPLC Method for the Estimation of Nadifloxacin, Terbinafine Hydrochloride, Mometasone Furoate, Methyl Paraben, and Propyl Paraben in Topical Pharmaceutical Dosage Form.
Bhosale, DM; Nikalje, APG, 2017
)
0.46
" Non-monotonic dose-response curves were obtained for BuPB (in both assays) and PG (in the luciferase assay), respectively."( Estrogenic and anti-estrogenic activity of butylparaben, butylated hydroxyanisole, butylated hydroxytoluene and propyl gallate and their binary mixtures on two estrogen responsive cell lines (T47D-Kbluc, MCF-7).
Cherfan, J; Drugan, T; Gutleb, AC; Kiss, B; Loghin, F; Lupu, D; Pop, A, 2018
)
0.48
" Data from live cell measurements were fit to a log-linear dose-response model."( A Ternary Mixture of Common Chemicals Perturbs Benign Human Breast Epithelial Cells More Than the Same Chemicals Do Individually.
Dairkee, SH; Goodson, WH; Jaffee, IM; Luciani-Torres, G; Moore, DH, 2018
)
0.48
" We observed a significant association for dose-response pattern of MePB [OR = 98."( Paraben Content in Adjacent Normal-malignant Breast Tissues from Women with Breast Cancer.
Amin, MM; Amjadi, E; Chavoshani, A; Ebrahimpour, K; Hashemi, M; Khazaei, S; Klishadi, R; Mansourian, M; Tabatabaeian, M, 2019
)
0.51
" After 7 days of exposure, BP reduced D1 activity in kidney in a dose-dependent manner, while decrease in D1 activity was significant only after dosing with BP1 for 21 days (p < 0."( Effects of butylparaben exposure on thyroid peroxidase (TPO) and type 1 iodothyronine deiodinase (D1) in female Wistar rats.
Gogoi, P; Kalita, JC, 2020
)
0.56
" Maximum MeP degradation (100%) was achieved after 90 min of irradiation with 750 mg/L RGOCdS dosage at an acidic pH of 3, for an initial MeP concentration of 30 mg/L."( Enhanced visible light-driven photocatalytic activity of reduced graphene oxide/cadmium sulfide composite: Methylparaben degradation mechanism and toxicity.
Karthi, N; Malathidevi, S; Mohan, H; Ramalingam, V; Seralathan, KK; Shin, T; Venkatachalam, J, 2021
)
0.62
"32 mg/g, when the pH of the extract solution (2), extraction time (35 min), extraction temperature (30°C), and adsorbent dosage (2 mg)."( Deep eutectic solvents cross-linked molecularly imprinted chitosan microsphere for the micro-solid phase extraction of p-hydroxybenzoic acid from pear rind.
Li, G; Row, KH, 2021
)
0.62
"01), while no significant dose-response relationship was found (p > 0."( Exposure to parabens and associations with oxidative stress in adults from South China.
Chen, Y; Gu, H; Hu, W; Li, C; Li, M; Liu, Y; Lu, S; Wu, X; Xiao, Q; Zhao, Y, 2021
)
0.62
" Pregnant mice were dosed daily by oral gavage with EtP at 0, 400, 800 and 1600 mg/kg or with PrP at 0, 625, 1250 and 2500 mg/kg from Day 1 of pregnancy until sacrifice."( Exposure to ethylparaben and propylparaben interfere with embryo implantation by compromising endometrial decidualization in early pregnant mice.
Cao, X; Chen, X; Ding, Y; Gao, R; Geng, Y; He, J; Li, F; Li, W; Liu, X; Peng, C; Tong, C; Wang, D; Wang, Y; Yang, C, 2021
)
0.91
" Paraben derivatives exhibit distinguished physiochemical properties that enable them to be compatible with the formulation of cosmetic agents in different dosage forms."( Implication of parabens in cosmetics and cosmeceuticals: Advantages and limitations.
Al-Adaileh, S; Al-Halaseh, LK; Al-Samydai, A; Dayyih, WA; Hajleh, MNA; Mbaideen, A; Zakaraya, ZZ, 2022
)
0.72
" Also, the effect of multiple dosing of parabens on p-gp expression was examined."( Evaluation of the Effect of Isobutyl Paraben and 2-ethyl Hexyl Paraben on P-glycoprotein Functional Expression in Rats: A Pharmacokinetic Study.
Alshogran, OY; Ghraiybah, NFA; I Al-Azzam, S, 2022
)
0.72
" Our novel findings reveal the health risks of exposure to low-level PCPs mixtures and further point out the overall dose-response relationship between DNA oxidative damage and PCP mixtures."( Assessment of health risk and dose-effect of DNA oxidative damage for the thirty chemicals mixture of parabens, triclosan, benzophenones, and phthalate esters.
Chen, C; Deng, Q; Dong, G; Hou, M; Huang, H; Liao, Q; Lv, Y; Ma, X; Peng, J; Wei, Q; Xiao, Y; Xing, X; Zeng, X; Zhang, X; Zhang, Z; Zheng, J; Zhu, X, 2022
)
0.72
" In addition, the dose-response relationship of plasma parabens with T2DM and glucose metabolism indicators were explored by the restricted cubic splines."( Exposure to parabens and dysglycemia: Insights from a Chinese population.
Huan, C; Huo, W; Jia, Z; Liao, W; Mao, Z; Nie, L; Song, Y; Wang, C; Wang, J; Wang, L; Wang, M; Wei, D; Xu, Q, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (47 Product(s))

Product Categories

Product CategoryProducts
Other14
Latticini, Cibi fermentati, Prodotti lattiero-caseari fermentati, Formaggi, Formaggi italiani, Grana Padano1
Snacks, Sweet snacks, Confectioneries1
Fertiggerichte, Fertigsalate, en:salads1
Plats préparés, Salades composées, Réfrigérés, Plats préparés réfrigérés, en:salads1
Aliments et boissons à base de végétaux,Aliments d'origine végétale,Légumineuses et dérivés,Conserves,Légumineuses,Aliments à base de plantes en conserve,Légumineuses en conserve,Haricots en conserve1
Plats préparés, Frais, Plats préparés frais, Taboulés, Taboulés frais1
Lanches comida,Lanches doces,Cacau e derivados,Chocolates,en:Chocolates with sweeteners,Chocolates amargos,en:Dark chocolates with sweeteners,Chocolates com avelãs,Chocolates negros com avelãs1
Surgelés1
Imbiss, Süßer Snack, Kekse und Kuchen, Kekse, Butterkekse1
Condiments, Sauces, Groceries1
Beauty & Personal Care23

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Aveeno Clear Complexion Foaming Cleanser -- 6 fl ozAveenoBeauty & Personal CareButylene Glycol, Citric Acid, Butylparaben, Citric Acid, Cocamidopropyl Betaine, Disodium Edta, Ethylparaben, Glycerin, Isobutylparaben, Methylparaben, Phenoxyethanol, Propylparaben2024-11-29 10:47:42
Aveeno Positively Smooth® Shave Gel -- 7 ozAveenoBeauty & Personal CareAllantoin, Benzyl Alcohol, Panthenol, Ethylparaben, Glycerin, Hydroxyethylcellulose, Isopentane, Methylparaben, Palmitic Acid, Palmitic Acid, Phenoxyethanol, Propylparaben, Sorbitol, Stearic Acid, Triethanolamine2024-11-29 10:47:42
Aveeno Therapeutic Shave Gel -- 7 ozAveenoBeauty & Personal CareAllantoin, Benzaldehyde, Panthenol, Ethylparaben, Glycerin, Hydroxyethylcellulose, Isopentane, Methylparaben, Oat, Palmitic Acid, Palmitic Acid, Phenoxyethanol, Propylparaben, Sorbitol, Stearic Acid, Triethanolamine2024-11-29 10:47:42
Biotene Dry Mouth Moisturizing Spray -- 1.5 fl ozBioteneBeauty & Personal Careglycerin, methylparaben, propylparaben, sodium benzoate, xylitol2024-11-29 10:47:42
Blue-Emu Original Blue Emu Super Strength -- 12 ozBlue-EmuBeauty & Personal Careallantoin, cetyl alcohol, cholecalciferol, panthenol, dimethyl sulfone, D glucosamine, glycerin, dimethicone, imidazolidinyl urea, methylparaben, oleyl alcohol, propylparaben, retinyl palmitate, stearic acid, triethanolamine2024-11-29 10:47:42
Blue-Emu Original Blue Emu Super Strength -- 4 ozBlue-EmuBeauty & Personal Careallantoin, cetyl alcohol, cholecalciferol, panthenol, dimethyl sulfone, D glucosamine, glycerin, dimethicone, imidazolidinyl urea, methylparaben, oleyl alcohol, propylparaben, retinyl palmitate, stearic acid, triethanolamine2024-11-29 10:47:42
CeraVe Daily Moisturizing Lotion for Normal to Dry Skin -- 12 fl ozCeraVeBeauty & Personal Carecarbomer, ceramide 3, cetyl alcohol, disodium edta, glycerin, dimethicone, methylparaben, phytosphingosine, potassium phosphate, propylparaben2024-11-29 10:47:42
CeraVe Facial Moisturizing Lotion AM with Sunscreen Broad Spectrum SPF 30 -- 3 fl ozCeraVeBeauty & Personal Carebht, carbomer, ceramide NP, cetearyl alcohol, disodium EDTA, glycerin, dimethicone, hydroxyethylcellulose, methylparaben, niacinamide, triethoxycaprylylsilane, phytosphingosine, propylparaben2024-11-29 10:47:42
CeraVe Foaming Facial Cleanser For Normal to Oily Skin -- 12 fl ozCeraVeBeauty & Personal Carecitric acid, carbomer, ceramide NP, citric acid, disodium EDTA, glycerin, methylparaben, niacinamide, phytosphingosine, propylene glycol, propylparaben, sodium lauroyl sarcosinate2024-11-29 10:47:42
CeraVe SA Body Lotion for Rough & Bumpy Skin with Salicylic Acid -- 8 fl ozCeraVeBeauty & Personal Careammonium lactate, carbomer, cetearyl alcohol, cetyl alcohol, cholecalciferol, disodium EDTA, glyceryl stearate, glycerin, dimethicone, methylparaben, phytosphingosine, propylparaben, salicylic acid, triethanolamine2024-11-29 10:47:42
Cococare Cocoa Butter Cream -- 15 ozCococareBeauty & Personal CareDMDM hydantoin, cetyl alcohol, EDTA, methylparaben, propylparaben, stearic acid, CI 191402024-11-29 10:47:42
Cococare Shea Butter Cream -- 15 ozCococareBeauty & Personal Carecetyl alcohol, EDTA, hydantoin, methylparaben, propylparaben, stearic acid2024-11-29 10:47:42
Earth Therapeutics Foot Repair Therapeutic Balm -- 4 ozEarth TherapeuticsBeauty & Personal CareAllantoin, Butylparaben, Carbomer, Cetyl Alcohol, Cholecalciferol, Vitamin E, Vitamin E, Isopropyl Palmitate, Lactic Acid, Methylparaben, Phenoxyethanol, Propylparaben, Retinyl Palmitate, Vitamin A, Stearic Acid, Triethanolamine, Urea2024-11-29 10:47:42
Earth Therapeutics Intensive Heel Repair -- 4 fl ozEarth TherapeuticsBeauty & Personal Carecitric acid, citric acid, vitamin E, vitamin E, glycerin, isopropyl palmitate, methylparaben, phenoxyethanol, propylparaben, retinyl palmitate, vitamin A, stearic acid, urea2024-11-29 10:47:42
Formula 10.0.6 Deep Down Detox Ultra-Cleansing Mud Mask -- 3.4 fl ozFormula 10.0.6Beauty & Personal Careorange, cetearyl alcohol, cetyl alcohol, tocopherol, tocopherol, kaolin, methylparaben, phenoxyethanol, PEG-40 stearate, propylparaben, stearic acid2024-11-29 10:47:42
Humble Brands Deodorant Vegan & Sensitive Skin Formula Mountain Lavender -- 2.5 ozHumble BrandsBeauty & Personal Careparabens, baking soda2024-11-29 10:47:42
NutriBiotic Skin Serum -- 1 fl ozNutriBioticBeauty & Personal Careascorbyl palmitate, CoQ10, tocopherol, DMAE, tocopherol, glycerin, imidazolidinyl urea, linalool, linoleic acid, mannitol, methylparaben, phenoxyethanol, propylparaben, retinyl palmitate, betasitosterol, sodium metabisulfite, alpha lipoic acid, tocotrienol, ubiquinone2024-11-29 10:47:42
NutriBiotic Super Shower Gel Fresh Fruit -- 12 fl ozNutriBioticBeauty & Personal Carecocamidopropyl betaine, vitamin E, diazolidinyl urea, sodium laureth sulfate, vitamin E, methylparaben, propylparaben, TRP2024-11-29 10:47:42
Oasis Moisturizing Mouth Spray for Dry Mouth Mild Mint -- 1 fl ozOasisBeauty & Personal Caremethylparaben, propylparaben, sodium benzoate2024-11-29 10:47:42
Physiogel Hypoallergenic Daily Moisture Therapy Dermo-Cleanser -- 5.1 fl ozPhysiogelBeauty & Personal Carecitric acid, butylparaben, cetearyl alcohol, citric acid, methylparaben, propylparaben2024-11-29 10:47:42
Tiger Balm Arthritis Rub Alcohol Free -- 4 fl ozTiger BalmBeauty & Personal Carediazolidinyl urea, methylsulfonylmethane, methyl paraben, propyl paraben2024-11-29 10:47:42
Tree to Tub Caffeine Eye Cream -- 0.5 fl ozTree to TubBeauty & Personal CareParabens2024-11-29 10:47:42
Tree to Tub Mandelic Acid 10% Gentle Exfoliating AHA Serum -- 1 fl ozTree to TubBeauty & Personal CareParabens2024-11-29 10:47:42

Roles (2)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
parabenA 4-hydroxybenzoate ester in which the esterifying alcohol is an alkanol (in diagram, R = alkyl). Commonly used as preservatives in cosmetic and pharmaceutical products.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (48)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency100.00000.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.41250.044717.8581100.0000AID485294
LuciferasePhotinus pyralis (common eastern firefly)Potency77.76220.007215.758889.3584AID1224835; AID624030
acetylcholinesteraseHomo sapiens (human)Potency1.78290.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency38.89523.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.06230.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency27.49980.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency48.55770.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency2.43370.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency24.51800.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency10.00000.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.79910.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency40.35410.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency19.33120.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency22.44580.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.24520.000214.376460.0339AID588532; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.68900.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.87560.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency2.16840.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency49.33820.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency20.68540.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588514; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency1.87690.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency26.51140.00108.379861.1304AID1645840
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency2.75360.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.01520.001019.414170.9645AID588537; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency36.30800.023723.228263.5986AID743222; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency35.39940.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency10.90960.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.30600.001628.015177.1139AID1259385
activating transcription factor 6Homo sapiens (human)Potency1.54860.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.51090.000323.4451159.6830AID743065; AID743066
histone deacetylase 9 isoform 3Homo sapiens (human)Potency38.82670.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.19370.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency15.35530.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency1.87690.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.87690.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency15.35530.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.77830.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.87690.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency76.95880.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency76.95880.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.87690.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)309.03000.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 beta isoform 1Homo sapiens (human)EC50 (µMol)300.00000.212522.156283.9400AID434954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,536)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990388 (15.30)18.7374
1990's223 (8.79)18.2507
2000's489 (19.28)29.6817
2010's949 (37.42)24.3611
2020's487 (19.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.02 (24.57)
Research Supply Index7.90 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index125.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (1.12%)5.53%
Reviews115 (4.31%)6.00%
Case Studies63 (2.36%)4.05%
Observational2 (0.07%)0.25%
Other2,457 (92.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]